Skip to main content
Clinical Trials/NCT04608136
NCT04608136
Completed
Not Applicable

Egg Yolk and Underlying Metabolisms on Modifying HDL Levels and Associated Genetics in Individuals With Metabolic Syndrome

Mahidol University1 site in 1 country76 target enrollmentSeptember 21, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Syndrome
Sponsor
Mahidol University
Enrollment
76
Locations
1
Primary Endpoint
Changes in electrolytes concentration following dietary intervention
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This research compare the effects of low carbohydrate intake and consumption of 3 eggs per day, and low energy diet on diabetes control and biomarkers of CVD in obese people.

Detailed Description

This research study examines the effects of changes in weight, metabolism of glucose and cholesterol in the blood through diet and behavior modification. The main objective of this study was to compare the effects of low carbohydrate intake and consumption of 3 eggs per day, and low energy diet on diabetes control and biomarkers of CVD in obese people. In addition, HDL quantity and size as well as HDL function was compared between the group who ate the whole egg and the group who did not eat the yolk.

Registry
clinicaltrials.gov
Start Date
September 21, 2020
End Date
December 31, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • weight stable \> 3 months (changing \< 5%)
  • three or more of the following five criteria are met 2.1 waist circumference ≥ 90 cm (men) or ≥ 80 cm (women) 2.2 fasting blood sugar ≥ 100 mg/dl 2.3 fasting triglyceride (TG) level ≥ 150 mg/dl 2.4 fasting high-density lipoprotein (HDL) cholesterol level ≤ 40 mg/dl (men) or ≤ 50 mg/dl (women) 2.5 blood pressure over 130/85 mmHg
  • can consume food that provided in project

Exclusion Criteria

  • consume drugs i.e. weight loss drugs, herbal pills, asthma drugs, steroid drugs, thyroid drugs, insulin injections, SGLT1 inhibitors drugs, SGLT2 inhibitors drugs, sulfonylurea drugs, blood lipid-lowering drugs
  • people who exercise vigorously (\> 150 minutes per week)
  • people who are or have weight loss by consuming less than 30% of carbohydrates, or are losing weight by other methods or who have eaten a specific diet as prescribed by a doctor within the past 6 months
  • people who drink alcohol more than once a week
  • people who had a LDL level within 6 months \> 190 mg/dl
  • fasting blood glucose levels \> 250 mg/dl and using diabetes drugs other than metformin
  • people with heart disease, type 1 diabetes, renal impairment \> level 3A
  • history of cancer, lung disease, gastrointestinal disease
  • people who smoke, people with eating disorder, people who have received psychiatric drugs
  • become a volunteer in a research project that is conducting a study related to food consumption

Outcomes

Primary Outcomes

Changes in electrolytes concentration following dietary intervention

Time Frame: Baseline and after 12 weeks

Na+ (mg/dl), K+ (mg/dl), Cl- (mg/dl) and HCO3- (mg/dl) concentration analysis

Changes in physical activity

Time Frame: Baseline and after 12 weeks

physical activity (MET-minutes/week) collect data by using questionnaires

Changes in betahydroxybutirate concentration following dietary intervention

Time Frame: Baseline and after 12 weeks

betahydroxybutirate (mmol/L) concentration analysis

Change from baseline Glycemia at 180 minutes

Time Frame: Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180

glucose (mg/dl)

Changes in weight following dietary intervention

Time Frame: Baseline and after 12 weeks

weight (kg) analysis

Changes in lipid profiles concentration following dietary intervention

Time Frame: Baseline and after 12 weeks

Triglycerides (mg/dl), Cholesterol (mg/dl), HDL-cholesterol (mg/dl) and LDL-cholesterol (mg/dl) concentration analysis

Changes in blood glucose and insulin concentration following dietary intervention

Time Frame: Baseline and after 12 weeks

HbA1C (%), glucose (mg/dl) and insulin (mg/dl) concentration analysis

Changes in body mass index following dietary intervention

Time Frame: Baseline and after 12 weeks

body mass index (kg/m\^2) analysis

Changes in waist circumference following dietary intervention

Time Frame: Baseline and after 12 weeks

waist circumference (cm) analysis

Change from baseline Insulin at 180 minutes

Time Frame: Minutes after intake of 75 g glucose: 0, 30, 60, 90, 120, 180

insulin (μU/ml)

Secondary Outcomes

  • Changes in carbohydrate following dietary intervention(Baseline and after 12 weeks)
  • Changes in fat intake following dietary intervention(Baseline and after 12 weeks)
  • Changes in energy intake following dietary intervention(Baseline and after 12 weeks)
  • Changes in protein intake following dietary intervention(Baseline and after 12 weeks)
  • Changes in blood pressure(Baseline and after 12 weeks)
  • Changes in fasting leptin levels(Baseline and after 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials